Study at a glance
Do inherited differences change how the vitamin D receptor works?
Researchers asked whether an inherited difference changes how the vitamin D receptor works. This receptor is a protein that helps cells respond to active vitamin D. They compared a shorter and a longer receptor in laboratory cells. They also examined human cells grown in the laboratory with different inherited combinations of the receptor forms.
Did the shorter and longer vitamin D receptors work differently?
The receptor forms differed in size, but the tests found no clear difference in how they attached to active vitamin D. No difference in attachment to DNA was detected either. Three laboratory tests of gene activity found no detectable difference in the level of active vitamin D needed to produce half the strongest response. The human cells also showed similar sensitivity in the one natural gene response tested.
Does finding no clear difference mean the receptors work exactly the same?
These experiments did not support a large difference in receptor performance caused by this inherited variation. However, failure to detect a difference is not proof that no difference exists. Small effects could have been below the tests’ ability to detect them.
Do these cell tests predict vitamin D responses in people?
Only selected gene responses and laboratory conditions were examined. The inherited difference might behave differently in other cell types or circumstances. The results cannot establish how well vitamin D works throughout a person’s body or predict health outcomes.
Read the full article below ↓This page provides a concise summary of a single verified primary study. For full methodological detail, measurement constraints, and inference boundaries, see the FokI Variants and Vitamin D Receptor Function: Full Evidence Review.
Study identity
Study type: Primary experimental laboratory study (receptor expression and functional assays, plus genotype-linked cell response testing)
Population or system studied: COS-7 cell expression system for VDR variants; cultured human fibroblasts stratified by genotype
Primary exposure or variable: VDR start codon polymorphism (FokI variants; F-VDR versus f-VDR) and fibroblast genotype (FF, Ff, ff)
Primary outcome category: Signalling efficiency proxies (ligand binding, DNA binding, transcriptional dose-response sensitivity, and endogenous target-gene induction)
Purpose of the study
This study tested a focused mechanistic question that sits underneath many broader discussions of vitamin D response variability: does a common vitamin D receptor (VDR) genetic variant measurably change receptor performance in classic receptor biology assays? The variant examined is the VDR start codon polymorphism (commonly referred to via the FokI restriction site), which produces two receptor proteins that differ in length by three amino acids at the N-terminus. That structural difference is biologically plausible as a source of altered signalling, but plausibility alone is not evidence.
The authors therefore approached the question in a disciplined, stepwise way: if one receptor form were meaningfully more or less efficient, the difference might appear first in fundamental receptor properties (ligand binding affinity, DNA binding capability) or in measurable signalling outputs (transcriptional activation sensitivity across a ligand dose range). The study also examined whether genotype predicts differences in an endogenous target-gene response in primary human cells (fibroblasts), to complement the controlled expression-system assays.
Study overview
The study compared the two receptor forms produced by the start codon polymorphism using multiple assay layers. In an expression system (COS-7 cells), the two VDR variants were expressed and confirmed as distinct at the protein level by differences in apparent size on Western blot. Receptor binding affinity for radiolabeled 1,25-dihydroxyvitamin D was then assessed, along with DNA binding capability using electrophoretic mobility shift assays.
To examine signalling responsiveness, the authors performed transactivation experiments using three different vitamin D responsive luciferase reporter constructs (linked to 24-hydroxylase, osteocalcin, and osteopontin regulatory elements). Dose-response curves were generated across a defined concentration range of 1,25-dihydroxyvitamin D, and ED50 values were compared between receptor forms as an operational measure of signalling sensitivity.
Finally, the study examined cultured human fibroblasts with FF, Ff, and ff genotypes and assessed sensitivity to 1,25-dihydroxyvitamin D by measuring induction of 24-hydroxylase mRNA, providing an endogenous gene response readout in genotype-defined primary cells.
Relevant receptor background: Vitamin D Receptors.
Key findings
The study confirmed that the two receptor forms are structurally distinguishable at the protein level in the expression system, consistent with the expected three amino acid difference. When the investigators tested ligand binding affinity using radiolabeled 1,25-dihydroxyvitamin D, they did not detect a significant difference in binding affinity between receptor forms under the assay conditions used. The authors explicitly noted assay-resolution constraints, meaning the correct interpretation is that no binding affinity difference was detectable with the method as applied, not that binding must be identical in every context.
In DNA binding assays (electrophoretic mobility shift assays), the study did not detect differences between receptor forms in DNA binding capability under the tested conditions. This indicates that gross DNA binding competence was similar in this assay framework, but it does not address more context-dependent aspects of genomic binding, such as chromatin accessibility or co-regulator landscapes, which are outside the scope of this methodology.
In reporter transactivation experiments, dose-response curves were generated for three different vitamin D responsive reporter constructs. ED50 values were reported as indistinguishable between receptor forms across the constructs tested. Within the operational logic of the study, this is the most direct test of signalling sensitivity in the assay framework: the receptor variants did not show a detectable shift in the ligand concentration required to reach half-maximal transcriptional activation in these reporter contexts.
In cultured human fibroblasts stratified by genotype (FF, Ff, ff), the study reported similar sensitivity to 1,25-dihydroxyvitamin D when measuring induction of 24-hydroxylase mRNA. Taken together, the findings indicate that, across the assay layers used (binding, DNA binding, reporter ED50, and one endogenous target-gene induction readout), the study did not identify major, easily measurable differences in receptor performance or signalling sensitivity attributable to this start codon polymorphism.
What this study shows
This study shows that, in the specific experimental systems and readouts tested, the VDR start codon polymorphism did not produce large, readily detectable differences in classic receptor biology measures (ligand binding affinity and DNA binding) or in a standard operational measure of signalling sensitivity (ED50 for transcriptional activation) across three reporter constructs. It also shows that, in the fibroblast system used, genotype was not associated with an obvious difference in induction sensitivity for a canonical vitamin D target gene (24-hydroxylase) under the tested conditions.
In practical interpretive terms, the study constrains a common explanatory shortcut: claims that this polymorphism causes a broad, large shift in VDR signalling efficiency that should be visible in baseline receptor assays are not supported by detectable differences in these assay frameworks.
What this study does not show
This study does not prove that the polymorphism has no functional impact in vivo. Null findings in defined assays cannot exclude subtle differences below assay sensitivity, differences that appear only in particular cellular environments, or differences that depend on promoter architecture, chromatin context, or co-regulator availability. It also does not demonstrate that the polymorphism is irrelevant to population-level phenotypes reported in other research; it only shows that a straightforward large-effect mechanism was not demonstrable in the tested receptor-level and reporter-level assays.
It also does not show that any observed variation in vitamin D-related outcomes across individuals is primarily explained by this polymorphism. Responsiveness can be shaped by many layers beyond receptor sequence, including tissue-specific metabolism and the separation between circulating status measures and tissue-level signalling outputs.
Relevant interpretation boundary background: Vitamin D Status vs Vitamin D Effect.
Limitations (high level)
The study’s conclusions are bounded by assay sensitivity and biological context. Binding assays and electrophoretic mobility shift assays have finite resolution; small functional differences can exist without being detectable under a given set of conditions. Reporter assays simplify promoter and chromatin context, and the three constructs used represent a limited sampling of possible genomic response architectures. The fibroblast experiments add endogenous transcriptional context but examine a single target gene induction response, which cannot represent the full spectrum of vitamin D receptor-mediated transcription across tissues.
Therefore, the correct use of this evidence is asymmetrical: it weakens claims of large, universal functional differences attributable to the start codon polymorphism in standard assay contexts, but it does not close the possibility of smaller or more context-specific effects outside those contexts.
Interpretation within vitamin D physiology
Within a physiology-first framework, this study is best read as a constraint on mechanistic narratives. Genetic variation in the receptor can, in principle, influence signalling, but this work indicates that a common start codon polymorphism does not necessarily translate into a large shift in baseline receptor performance metrics or a clear shift in transcriptional sensitivity in classic reporter systems. If this polymorphism influences real-world physiology, the mechanism may be subtle, dependent on specific tissue contexts, or mediated through interactions not captured by the assay set used here.
This matters for interpretation because receptor genetics is often invoked to explain why vitamin D studies disagree or why individuals respond differently. This study suggests that at least one plausible candidate mechanism (a large change in receptor binding, DNA binding, or ED50 sensitivity) is not an evidence-backed default assumption for this polymorphism. It pushes interpretation toward a more layered model in which genotype may contribute, but not necessarily through large-effect shifts in canonical receptor properties.
For relevant physiology background, see Vitamin D Receptor Polymorphisms.
Relevant genetics background: Vitamin D Genetics.
Primary source and publication details
Gross C, Krishnan AV, Malloy PJ, Eccleshall TR, Zhao XY, et al.
The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants
J Bone Miner Res. 1998.
DOI: 10.1359/jbmr.1998.13.11.1691
https://pubmed.ncbi.nlm.nih.gov/9797477
Related reading
Inherited Variation in Vitamin D Genes and Type 1 Diabetes Predisposition
The etiology and pathophysiology of type 1 diabetes remain largely elusive with no established concepts for a causal therapy.
Original paper ↗Read more →Relationship Between the ApaI (rs7975232), BsmI (rs1544410), FokI (rs2228570), and TaqI (rs731236) Variants in the Vitamin D Receptor Gene and Urolithiasis Susceptibility: An Updated Meta-Analysis and Trial Sequential Analysis
Trial sequential analysis results were on a sufficiently large number of participants and did not require more research to confirm associations.
Original paper ↗Read more →VDR Gene Polymorphisms (BsmI, FokI, TaqI, ApaI) in Total Hip Arthroplasty Outcome Patients
A total hip arthroplasty (THA) can improve quality of life, but loosening of the hip prosthesis is a complex problem in which vitamin D may also play a role.
Original paper ↗Read more →Vitamin D Receptor FokI, ApaI, and TaqI Polymorphisms in Lead Exposed Subjects From Saudi Arabia
This study examined the polymorphisms in exon 2 (allele 1) and intron 8 (allele 2 and allele 3) of VDR gene and their relation to BLLs.
Original paper ↗Read more →Vitamin D Receptor Gene Variants Associated with Serum 25(OH)D3 Levels in Patients with Dry Eye Syndrome
Objective: The aim of this study was to investigate the association between serum 25-hydroxyvitamin D [25(OH)D3] levels and selected polymorphisms in the VDR gene (Taq, Fok, Apa, and Bsm) in patients with DES and to analyze their potential clinical and genetic interactions.
Original paper ↗Read more →Vitamin D Receptor (VDR) Genetic Variants: Relationship of FokI Genotypes with VDR Expression and Clinical Disease Activity in Systemic Lupus Erythematosus Patients
This study was aimed to determine the association of the VDR variants FokI (rs2228570), BsmI (rs1544410), ApaI (rs7975232), and TaqI (rs731236) with susceptibility to the disease, VD status, VDR mRNA expression, and clinical disease activity in SLE patients.
Original paper ↗Read more →FokI Variants and Vitamin D Receptor Function: Full Evidence Review
Full evidence review of a verified primary laboratory study testing whether the VDR start-codon polymorphism (FokI) produces measurable differences in ligand binding, DNA binding, and transcriptional transactivation, with strict inference boundaries and assay-sensitivity limits.
Read more →VDR FokI, Receptor Expression and Linked Haplotypes: Evidence Synthesis
Explore how common VDR polymorphisms including FokI, BsmI, ApaI and TaqI may influence receptor function, expression and vitamin D signalling.
Read more →FokI Polymorphism in the Vitamin D Receptor Gene (VDR) and Its Association with Lumbar Spine Pathologies in the Italian Population: A Case-Control Study
Alterations in vitamin D homeostasis, mainly involving its nuclear receptor (VDR), could have a role in the pathophysiology of the spine.
Original paper ↗Read more →High-Throughput Gene and Protein Analysis Revealed the Response of Disc Cells to Vitamin D, Depending on the VDR FokI Variants
The present study was aimed at investigating, through high-throughput gene and protein analysis, the response of human disc cells to vitamin D, depending on the VDR FokI variants.
Original paper ↗Read more →Vitamin D receptor gene BsmI, FokI, ApaI and TaqI polymorphisms and the risk of systemic lupus erythematosus
Recently, several studies have demonstrated the role of vitamin D receptor (VDR) polymorphisms in the development of systemic lupus erythematosus (SLE); however, these results are inconsistent between different cohorts.
Original paper ↗Read more →Interactions between Serum Vitamin D Levels and Vitamin D Receptor Gene FokI Polymorphisms for Renal Function in Patients with Type 2 Diabetes
We aimed to examine associations among serum 25-hydroxyvitamin D (25OHD) levels, 1,25-dihyroxyvitamin D (1,25OHD) levels, vitamin D receptor (VDR) polymorphisms, and renal function based on estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes.
Original paper ↗Read more →Vitamin D Receptor Gene Expression and Function in a South African Population: Ethnicity, Vitamin D and FokI
Polymorphisms of the vitamin D receptor gene (VDR) have been associated inconsistently with various diseases, across populations of diverse origin.
Original paper ↗Read more →Association between Single Nucleotide Polymorphism of Vitamin D Receptor Gene FokI Polymorphism and Clinical Progress of Benign Prostatic Hyperplasia
The aim of the study was to investigate the association between single nucleotide polymorphism (SNP) of vitamin D receptor (VDR) gene and clinical progress of benign prostatic hyperplasia (BPH) in Chinese men.
Original paper ↗Read more →Low back pain and FokI (rs2228570) polymorphism of vitamin D receptor in athletes
We investigated whether carriage of a specific genotype and/or allele of vitamin D receptor gene (VDR) FokI polymorphism (rs2228570) was a risk factor for LBP in athletes of different sports disciplines.
Original paper ↗Read more →The Impact of Vitamin D Receptor Gene Polymorphisms (FokI, ApaI, TaqI) in Correlation with Oxidative Stress and Hormonal and Dermatologic Manifestations in Polycystic Ovary Syndrome
Background and Objectives: Polycystic ovary syndrome (PCOS) is a frequent and complex multidisciplinary disorder.
Original paper ↗Read more →Vitamin D deficiency and vitamin D receptor FokI polymorphism as risk factors for COVID-19
Given the sparse data on vitamin D status in pediatric COVID-19, we investigated whether vitamin D deficiency could be a risk factor for susceptibility to COVID-19 in Egyptian children and adolescents.
Original paper ↗Read more →Allelic variants in vitamin D receptor gene are associated with adiposity measures in the central-European population
The AC genotype of ApaI SNP was associated with reduced waist circumference compared to AA genotype (β = −4.37, 95% CI: -7.54;-1.20; p = 0.007).
Original paper ↗Read more →Association of vitamin D receptor variants with clinical parameters in prostate cancer
Prostate Cancer (PCa) is one of the most common cancers in men and its early detection can provide a high chance of cure.
Original paper ↗Read more →Evaluating the Role of BglI rs739837 and TaqI rs731236 Polymorphisms in Vitamin D Receptor with SARS-CoV-2 Variants Mortality Rate
This study aimed to evaluate the relationship between the BglI rs739837 and TaqI rs731236 polymorphisms and the mortality rate of COVID-19 based on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants.
Original paper ↗Read more →Fok-I, Bsm-I, and Taq-I Variants of Vitamin D Receptor Polymorphism in the Development of Autism Spectrum Disorder: A Literature Review
The role of vitamin D in the development of autism spectrum disorder (ASD) is of intensified interest in medical science in recent years.
Original paper ↗Read more →Original sources
https://pubmed.ncbi.nlm.nih.gov/9797477
https://pubmed.ncbi.nlm.nih.gov/9797477.
Publication details
https://pubmed.ncbi.nlm.nih.gov/9797477